Skip to main content

Clinical Pharmacokinetics of Phenytoin

Summary

Phenytoin is a relatively insoluble weak acid, usually administered as the sodium salt.

Bioavailability is dependent upon particle size and problems of generic inequivalence have therefore arisen, particularly in Scandinavia. The drug has a moderately large volume of distribution and is approximately 90% bound to plasma proteins. Clinically important displacement can be caused by bilirubin and several drugs, particularly sodium valproate, which is often combined with Phenytoin. Displacement will lower the total serum concentration but will little affect the free drug concentration.

The metabolism of Phenytoin to the major metabolite, 5-(p-hydroxyphenyl)-5-(phenylhydantoin, is saturable, giving rise to a non linear dose-serum concentration relationship. Therefore, the dose range compatible with a therapeutic serum concentration is narrow within subjects, and monitoring serum concentrations is of particular value in dosage tailoring. In renal failure, the binding of phenytoin to plasma proteins is reduced and therefore a lower range of serum drug concentrations is compatible with therapeutic control. In liver disease, binding may also be impaired but delayed metabolism may occur in addition. During pregnancy the serum concentration may fall progressively as pregnancy advances, probably due to an increased rate of metabolism. Phenytoin readily crosses the placenta, and is metabolised rapidly by the neonate exposed in utero.

This is a preview of subscription content, access via your institution.

References

  • Arnold. K. and Gerber, N.: The rate of decline of diphenylhydantoin in human plasma. Clinical Pharmacology and Therapeutes 2: 121–134 (1970).

    Google Scholar 

  • Barot, M.H.; Grant, R.H.E.; Maheendran, K.K.; Mawer, G.E. and Woodcock, B.G.: Individual variation in daily dosage requirements for Phenytoin sodium in patients with epilepsy. British Journal of Clinical Pharmacology 6: 267–271 (1978).

    PubMed  CAS  Article  Google Scholar 

  • Barth, N.; Alvan, G.; Borga, O. and Sjoqvist, F.: Twofold interindividual variation in plasma protein binding of Phenytoin in patients with epilepsy. Clinical Pharmacokinetics 1: 444–452 (1976).

    PubMed  CAS  Article  Google Scholar 

  • Bochner, F.; Hooper, W.D.; Sutherland, J.M.; Eadie, M.J. and Tyrer, J.H.: The renal handling of diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin. Clinical Pharmacology and Therapeutics 14: 791–796 (1973).

    PubMed  CAS  Google Scholar 

  • Bochner, F.; Hooper. W.D.; Sutherland, J.M.; Eadie, M.J. and Tyrer, J.H.: Diphenylhydantoin concentrations in saliva. Archives of Neurology (Chicago) 31: 57–59 (1974).

    CAS  Article  Google Scholar 

  • Boobis, S.W.: Alteration of plasma albumin in relation to decreased drug binding in uremia. Clinical Pharmacology and Therapeutics 22: 147–153 (1977).

    PubMed  CAS  Google Scholar 

  • Booker, H.E. and Darcey, B.: Serum concentration of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia 14: 177–184 (1973).

    PubMed  CAS  Article  Google Scholar 

  • Borga, O.; Juhlin Dannfeidt, A. and Dahlqvist, R.: Plasma levels and protein binding of Phenytoin during exercise in man: the effect of elevated free fatty acids. Pharmacology 16: 37–43 (1978).

    PubMed  CAS  Article  Google Scholar 

  • Borofsky, L.G.; Louis, S.; Kutt, H. and Roginsky, M.: Diphenylhydantoin: efficacy toxicity and dose-serum level relationship in children. Journal of Pediatrics 81: 995–1002 (1972).

    PubMed  CAS  Article  Google Scholar 

  • Buchanan, R.A.; Turner, J.L.; Moyer, C.F. and Heffelfinger, J.C: Single daily dose of diphenylhydantoin in children. Journal of Paediatrics 83: 479–483 (1973).

    CAS  Article  Google Scholar 

  • Buchthal, F. and Lennox-Buchthal, M.A.: Diphenylhydantoin. Relation of anticonvulsant effect to concentration in serum; in Woodbury, Penry and Schmidt (Eds) Antiepileptic Drugs p. 335 (Raven Press, New York 1972).

    Google Scholar 

  • Buchthal, F.; Svensmark, O. and Schiller, P.J.: Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. Archives of Neurology (Chicago) 2: 624–630 (1960).

    CAS  Article  Google Scholar 

  • Christiansen, J. and Dam, M.: Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurologica Scandinavica 49: 543–546 (1973).

    PubMed  CAS  Article  Google Scholar 

  • Cocks, D.A.; Critchley, E.M.R.; Hayward, H.W.; Owen, V.; Mawer, G.E. and Woodcock, B.G.: Control of epilepsy with a single daily dose of Phenytoin sodium. British Journal of Clinical Pharmacology 2: 449–453 (1975).

    PubMed  CAS  Article  Google Scholar 

  • Colbura, W.A. and Gibaldi, M.: Plasma protein binding and metabolic clearance of Phenytoin in the rat. Journal of Pharmacology and Experimental Therapeutics 203: 500–506 (1977).

    Google Scholar 

  • Cook, C.E.; Amerson, E.; Poole, W.K.; Lesser, P. and O’Tuama, L.: Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay. Clinical Pharmacology and Therapeutics 18: 742–747 (1975).

    PubMed  CAS  Google Scholar 

  • Dam, M.; Christiansen, J.; Munck, O. and Mygind, K.I.: Antiepileptic drugs: Metabolism in pregnancy. Clinical Pharmacokinetics 4: 53 (1979).

    PubMed  CAS  Article  Google Scholar 

  • Dill, W.A.; Kazenko, A.; Wolf, L.M. and Glazko, A.J.: Studies on 5,5′-diphenylhydantoin (Dilantin) in animals and man. Journal of Pharmacology and Experimental Therapeutics 118: 270–279 (1956).

    PubMed  CAS  Google Scholar 

  • Eadie, M.J.; Lander, C.M. and Tyrer, J.H.: Plasma drug level monitoring in pregnancy. Clinical Pharmacokinetics 2: 427–436 (1977).

    PubMed  CAS  Article  Google Scholar 

  • Eadie, M.J. and Tyrer, J.H.: Anticonvulsant Therapy Pharmacological Basis and Practice (Churchill Livingstone, Edinburgh 1974).

    Google Scholar 

  • Eadie, M.J.; Tyrer, J.H. and Hooper, W.D.: Diphenylhydantoin dosage. Proceedings of the Australian Association of Neurologists 10: 53–59 (1973).

    PubMed  CAS  Google Scholar 

  • Eadie, M.J.; Tyrer, J.H.; Bochner, F. and Hooper, W.D.: The elimination of Phenytoin in man. Clinical and Experimental Pharmacology and Physiology 3: 217–224 (1976).

    PubMed  CAS  Article  Google Scholar 

  • Ehrnebo, M.; Agurell, S.; Jalling, B. and Boreus, L.O.: Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. European Journal of Clinical Pharmacology 3: 189–193 (1971).

    PubMed  CAS  Article  Google Scholar 

  • Ehrnebo, M. and Odar-Cederlof, I.: Distribution of pentobarbital and diphenylhydantoin between plasma and cells in blood: effect of salicylic acid, temperature and total drug concentration. European Journal of Clinical Pharmacology 11: 37–42 (1977).

    PubMed  CAS  Article  Google Scholar 

  • Fredholm, B.B.; Rane, A. and Persson, B.: Diphenylhydantoin binding to proteins in plasma and its dependence on free fatty acid and bilirubin concentration in dogs and newborn infants. Pediatric Research 9: 26–30 (1975).

    CAS  Article  Google Scholar 

  • Frigo, G.M.; Liccini, S.; Gatti, G.; Perucca, E. and Crema, A.: Modification of Phenytoin clearance by valproic acid in normal subjects. British Journal of Clinical Pharmacology (In press, 1979).

  • Garrettson, L.K. and Jusko, W.J.: Diphenylhydantoin kinetics in overdosed children. Clinical Pharmacology and Therapeutics 17: 481–491 (1975).

    PubMed  CAS  Google Scholar 

  • Gerber, N.; Lynn, R.; Bush, M. and Oates, J.: Relationship of plasma level of diphenylhydantoin (DPH) to the rate of excretion of urinary HPPH. Clinical Pharmacology and Therapeutics 13: 139 (1972).

    Google Scholar 

  • Gerber, N. and Wagner, J.G.: Explanation of dose dependent decline of DPH plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Research Communications in Chemical Pathology and Pharmacology 3: 455–466 (1972).

    PubMed  CAS  Google Scholar 

  • Glazko, A.J.: Diphenylhydantoin metabolism. A prospective review. Drug Metabolism and Disposition 1: 711–714 (1973).

    CAS  Google Scholar 

  • Glazko, A.J.; Chang. T.; Maschewske, E.; Hayes, A. and Dill, A.W.: Role of hydroxylated metabolites of Phenytoin in dose dependency; in proceedings of the Third International Symposium on Microsomes and Drug Oxidation (Pergamon Press, Berlin 1979).

    Google Scholar 

  • Gugler, R.; Manion, C.V. and Azarnoff, D.L.: Phenytoin: pharmacokinetics and bioavailability. Clinical Pharmacology and Therapeutics 19: 135–142 (1976).

    PubMed  CAS  Google Scholar 

  • Haerer, A.F. and Grace, J.B.: Studies of anticonvulsant levels in epileptics. Serum diphenylhydantoin concentrations in a group of medically indigent outpatients. Acta Neurologica Scandinavica 45: 18–31 (1969).

    CAS  Google Scholar 

  • Hanisotia, P. and Keran, E.: Diphenylhydantoin binding by red blood cells of normal subjects. Neurology (Minneapolis) 24: 575–578 (1974).

    Article  Google Scholar 

  • Hansen, J.M.; Kristensen, M.; Skovsted, L. and Christensen, L.K.: Dicoumarol induced diphenylhydantoin intoxication. Lancet 2: 265–266 (1966).

    PubMed  CAS  Article  Google Scholar 

  • Hayes, M.J.; Langman, M.J.S. and Short, A.H.: Changes in drug metabolism with increasing age: 2. Phenytoin clearance and protein binding: British Journal of Clinical Pharmacology 2: 73–79 (1975).

    PubMed  CAS  Google Scholar 

  • Hooper, W.D.; Bochner, F.; Eadie, M.J. and Tyrer, J.H.: Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clinical Pharmacology and Therapeutics 15: 276–282 (1974).

    CAS  Google Scholar 

  • Hoppel, C.; Carle, M.; Rane, A. and Sjoqvist, F.: Plasma concentrations of 5-(p-hydroxyphenyl)-5-phenylhydantoin in diphenylhydantoin treated patients. Clinical Pharmacology and Therapeutics 21: 294–300 (1977).

    PubMed  CAS  Google Scholar 

  • Houghton, G.W. and Richens, A.: Rate of elimination of tracer doses of Phenytoin at different steady-state serum concentrations in epileptic patients. British Journal of Clinical Pharmacology 1: 155–161 (1974a).

    PubMed  CAS  Article  Google Scholar 

  • Houghton, G.W. and Richens, A.: Inhibition of Phenytoin metabolism by sulthiame in epileptic patients. British Journal of Clinical Pharmacology 1: 59–66 (1974b).

    PubMed  CAS  Article  Google Scholar 

  • Houghton, G.W. and Richens, A.: The effect of benzodiazepines and pheneturide on Phenytoin metabolism in man. British Journal of Clinical Pharmacology 1: 344–345 (1974c).

    Google Scholar 

  • Houghton, G.W.; Richens, A. and Leighton, M.: Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. British Journal of Clinical Pharmacology 2: 251–256 (1975a).

    PubMed  CAS  Article  Google Scholar 

  • Houghton, G.W.; Richens, A.; Toseland, P.A.; Davidson, S. and Falconer, M.A.: Brain concentrations of phenytoin, phenobarbitone and primidone in epileptic patients. European Journal of Clinical Pharmacology 9: 73–78 (1975b).

    PubMed  CAS  Article  Google Scholar 

  • Hunter, J.: Enzyme induction and inhibition in human pregnancy; in Richens and Woodford (Eds) Anticonvulsant Drugs and Enzyme Induction, p. 131 (Associated Scientific Publishers, Amsterdam 1976).

    Google Scholar 

  • Jailing, B.; Boreus, L.D.; Rane. A. and Sjoqvist, F.: Plasma concentrations of diphenylhydantoin in young infants. Pharmacologia Clinica 2: 200–202 (1970).

    Article  Google Scholar 

  • Kaneko, S.; Sato, T. and Suzuki, K.: The levels of anticonvulsants in maternal milk. British Journal of Clinical Pharmacology (In press. 1979).

  • Karlen, B.; Garle, M.: Rane, A.: Gutova, M. and Lindeborg, B.: Assay of diphenylhydantoin (phenytoin) metabolites in urine by gas chromatography. Metabolite pattern in humans. European Journal of Clinical Pharmacology 8; 359–363 (1975).

    PubMed  CAS  Article  Google Scholar 

  • Kater, R.M.H.; Roggin, G.; Tobon, F.; Zieve, P. and Iber, P.L.: Increased rate of clearance of drugs from the circulation of alcoholics. American Journal of Medical Science 258: 35–39 (1969).

    CAS  Article  Google Scholar 

  • Knight, A.H. and Rhind, E.G.: Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia 16: 99–110 (1975).

    PubMed  CAS  Article  Google Scholar 

  • Krauer, B. and Krauer, F.: Drug kinetics in pregnancy. Clinical Pharmacokinetics 2: 167–181 (1977).

    PubMed  CAS  Article  Google Scholar 

  • Kurata, D. and Wilkinson, G.R.: Erythrocyte uptake and plasma binding of diphenylhydantoin. Clinical Pharmacology & Therapeutics 16: 355–362 (1974).

    CAS  Google Scholar 

  • Kutt, H.: Diphenylhydantoin. Interactions with other drugs in man; in Woodbury. Penry and Schmidt (Eds) Antiepileptic Drugs, p. 168 (Raven Press. New York 1972).

    Google Scholar 

  • Kutt, H.: Winters, W.; Kokenge, R. and McDowell, F.: Diphenylhydantoin metabolism, blood levels and toxicity. Archives of Neurology (Chicago) 11: 642–647 (1964a).

    CAS  Article  Google Scholar 

  • Kutt, H.; Winters, W.: Scherman, R. and McDowell, F.: Diphenylhydantoin and phenobarbital toxicity. The role of liver disease. Archives of Neurology (Chicago) 11: 649–656 (1964b).

    CAS  Article  Google Scholar 

  • Kutt, H.: Winters, W. and McDowell, F.; Depression of parahydroxylation of diphenylhydantoin by antituberculous chemotherapy. Neurology (Minneapolis) 16: 594–602 (1966).

    CAS  Google Scholar 

  • Lascelles, P.T.; Kocen, R.S. and Reynolds, E.H.: The distribution of plasma phenytoin levels in epileptic patients. Journal of Neurology. Neurosurgery and Psychiatry 33: 501–505 (1970).

    CAS  Article  Google Scholar 

  • Letteri, J.M.; Mellk, H.; Louis, S.; Kutt, H.; Durante, P. and Glazko, A.J.: Diphenylhydantoin metabolism in uremia. New England Journal of Medicine 285: 648–652 (1971).

    PubMed  CAS  Article  Google Scholar 

  • Levy, G.: Pharmacokinetic approaches to the study of drug interactions. Annals of the New York Academy of Science 281: 24–39 (1976).

    CAS  Article  Google Scholar 

  • Loeser, E.W.: Studies on the metabolism of diphenylhydantoin (Dilantin). Neurology (Minneapolis) 11: 424–429 (1961).

    CAS  Article  Google Scholar 

  • Lund, L.: Clinical significance of generic inequivalence of three different pharmaceutical preparations of phenytoin. European Journal of Clinical Pharmacology 7: 119–124 (1974a).

    PubMed  CAS  Article  Google Scholar 

  • Lund, L.: Anticonvulsant effects of diphenylhydantoin relative to plasma levels. A prospective 3-year study in ambulant patients with generalized epileptic seizures. Archives of Neurology (Chicago) 31: 289–294 (1974b).

    CAS  Article  Google Scholar 

  • Lund, L.; Berlin, A. and Lunde, P.K.M.: Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid. Clinical Pharmacology and Therapeutics 13: 196–200 (1972).

    CAS  Google Scholar 

  • Lunde, P.K.M.; Rane, A.; Yaffe, S.J.; Lund, L. and Sjoqvist, F.: Plasma protein binding of diphenylhydantoin in man: interaction with other drugs and the effect of temperature and plasma dilution. Clinical Pharmacology and Therapeutics 11: 844–855 (1970).

    Google Scholar 

  • Mattson, R.H.; Cramer, J.A.; Williamson, P.D. and Novelly, R.A.: Valproic acid in epilepsy; clinical and pharmacological effects. Annals of Neurology 3: 20–25 (1978).

    PubMed  CAS  Article  Google Scholar 

  • Mawer, G.E.; Mullen, P.W.; Rodgers, M.; Robins, A.J. and Lucas, S.B.: Phenytoin dose adjustment in epileptic patients. British Journal of Clinical Pharmacology 1: 163–168 (1974).

    PubMed  CAS  Article  Google Scholar 

  • Monks, A.: Binding of phenytoin and valproic acid by human serum proteins. PhD Thesis, University of London (1978).

  • Monks, A. and Richens, A.: Effect of a single dose of sodium valproate on serum phenytoin concentration and protein binding in epileptic patients. Clinical Pharmacology and Therapeutics (In press, 1979).

  • Monks, A.; Boobis, S.; Wadsworth, J. and Richens, A.: Plasma protein binding interaction between phenytoin and valproic acid in vitro. British Journal of Clinical Pharmacology 6: 487–492 (1978).

    PubMed  CAS  Article  Google Scholar 

  • Mullen, P.W.: Optimal phenytoin therapy: a new technique for individualizing dosage. Clinical Pharmacology and Therapeutics 23: 228–232 (1978).

    PubMed  CAS  Google Scholar 

  • Mullen, P.W. and Foster, R.W.: Comparative evaluation of six techniques for determining the Michaelis-Menten parameters relating phenytoin dose and steady-state serum concentrations. Journal of Pharmacy and Pharmacology 31; 100–104 (1979).

    PubMed  CAS  Article  Google Scholar 

  • Mygind, K.J.; Dam, M. and Christiansen, J.: Phenytoin and phenobarbitone plasma clearance during pregnancy. Acta Neurologica Scandinavica 54: 160–166 (1976).

    PubMed  CAS  Article  Google Scholar 

  • Neuvonen, P.J.: Bioavailability of phenytoin: Clinical, pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics 4: 91 (1979).

    PubMed  CAS  Article  Google Scholar 

  • Odar-Cederlof, I.: Plasma protein binding of Phenytoin and warfarin in patients undergoing renal transplantation. Clinical Pharmacokinetics 2: 147 (1977).

    PubMed  CAS  Article  Google Scholar 

  • Odar-Cederlof, I. and Borga, O.: Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. European Journal of Clinical Pharmacology 7: 31–37 (1974).

    PubMed  CAS  Article  Google Scholar 

  • Odar-Cederlof, I. and Borga, O.: Lack of relationship between serum free fatty acids and impaired plasma protein binding of diphenylhydantoin in chronic renal failure. European Journal of Clinical Pharmacology 10: 403–405 (1976a).

    PubMed  CAS  Article  Google Scholar 

  • Odar-Cederlof, I. and Borga, O.: Impaired protein binding of Phenytoin in uremia and displacement effects of salicylic acid. Clinical Pharmacology and Therapeutics 20: 36–47 (1976b).

    PubMed  CAS  Google Scholar 

  • Paxton, J.W.; Whiting. B. and Stephen, K.W.: Phenytoin concentrations in mixed parotid and submandibular saliva and serum measured by radioimmunoassay. British Journal of Clinical Pharmacology 4: 185–192 (1977).

    PubMed  CAS  Article  Google Scholar 

  • Pentikainen, P.J.; Neuvonen, P.J. and Elfving, S.M.: Bioavailability of four brands of Phenytoin tablets. European Journal of Clinical Pharmacology 1 213–218 (1975).

    Article  Google Scholar 

  • Perucca, E.: Clinical consequences of microsomal enzyme induction by antiepileptic drugs. Journal of Clinical Pharmacology and Therapeutics (In press, 1979).

  • Perucca, E.; Makki, K. and Richens, A.: Is Phenytoin metabolism dose dependent by enzyme saturation or by feedback inhibition?. Clinical Pharmacology and Therapeutics 22: 46–51 (1978).

    Google Scholar 

  • Perucca, E. and Richens, A.: Anticonvulsant drug interactions in epilepsy; in Tyrer (Ed) Current Status of Modern Therapy. (M.T.P. Press, Lancaster 1979).

    Google Scholar 

  • Pippenger, C.E.; Paris-Kutt, H.; Penry, J.K. and Daly, D.D.; Anti-epileptic drug levels quality control program: interlaboratory variability; in Pippenger (Ed) Antiepileptic Drugs: Quantitative Analysis and Interpretation, p. 187 (Raven Press, New York 1978).

    Google Scholar 

  • Pippenger, C.E.; Penry, J.K., White, B.G.; Daly, D.D. and Buddington, R.: Interlaboratory variability in determination of plasma antiepileptic drug concentrations. Archives of Neurology (Chicago) 33: 351–355 (1976).

    CAS  Article  Google Scholar 

  • Porter, R.J. and Layzer, R.B.: Plasma albumin concentration and diphenylhydantoin binding in man. Archives of Neurology (Chicago) 32: 298–303 (1975).

    CAS  Article  Google Scholar 

  • Rambeck, B.; Boenigk, H.E.; Dunlop, A.; Mullen, P.W.; Wadsworth, J. and Richens, A.: Predicting Phenytoin dose: a revised nomogram. Therapeutic Drug Monitoring (In press, 1979).

  • Rambeck, B.; Boenigk, H.E. and Stenzel, E.: Bioavailability of three phenytoin preparations in healthy subjects and in epileptics. European Journal of Clinical Pharmacology 12: 285–290 (1977).

    PubMed  CAS  Article  Google Scholar 

  • Rane, A.: Clinical pharmacokinetics of antiepileptic drugs in children. Journal of Clinical Pharmacology and Therapeutics (In press, 1979).

  • Rane, A.; Garle, M.; Borga, O. and Sjoqvist, F.; Plasma disappearance of transplacentally transferred Phenytoin in the newborn studied with mass fragmentography. Clinical Pharmacology and Therapeutics 15: 39–45 (1974).

    PubMed  CAS  Google Scholar 

  • Rane, A.; Lunde, P.K.M.; Jailing, B.; Yaffe, S.J. and Sjoqvist, F.: Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinaemic infants. Journal of Pediatrics 78: 877–882 (1971).

    PubMed  CAS  Article  Google Scholar 

  • Reidenberg, M.M.; Odar-Cederloff, I.; Von Bahr, C.; Borga, O. and Sjoqvist, F.: Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. New England Journal of Medicine 285; 264–267 (1971).

    PubMed  CAS  Article  Google Scholar 

  • Reynolds, F.; Ziroyanis, P.; Jones, N. and Smith, S.E.: Salivary Phenytoin concentrations in epilepsy and in chronic renal failure. Lancet 2: 384–386 (1976).

    PubMed  CAS  Article  Google Scholar 

  • Richens, A.; A study of the pharmacokinetics of Phenytoin (diphenylhydantoin) in epileptic patients and the development of a nomogram for making dose increments. Epilepsia 16: 627–646 (1975a).

    PubMed  CAS  Article  Google Scholar 

  • Richens, A.: Results of a phenytoin quality control scheme; in Schneider (Ed) Clinical Pharmacology of Antiepileptic Drugs, p. 293 (Springer Verlag, Heidelberg 1975b).

    Chapter  Google Scholar 

  • Richens, A.: Drug Treatment of Epilepsy (Henry Kimpton, London 1976).

    Google Scholar 

  • Richens, A.: Interactions with antiepileptic drugs. Drugs 13: 266–275 (1977).

    PubMed  CAS  Article  Google Scholar 

  • Richens, A.: Drug level monitoring — quality and quantity. British Journal of Clinical Pharmacology 5: 285–286 (1978).

    Article  Google Scholar 

  • Richens, A. and Dunlop, A.: Serum phenytoin levels in the management of epilepsy. Lancet 2: 247–248 (1975).

    PubMed  CAS  Article  Google Scholar 

  • Robinson, J.D.; Morris, B.A.; Aherne, G.W. and Marks, V.: Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay. British Journal of Clinical Pharmacology 2: 345–350 (1975).

    PubMed  CAS  Article  Google Scholar 

  • Roe, M.D.; Podosin, R.L. and Blaskovics, M.: Drug interaction: diazoxide and diphenylhydantoin. Journal of Paediatrics 87: 480–484 (1975).

    CAS  Article  Google Scholar 

  • Schmidt, D. and Kupferberg, H.: Diphenylhydantoin, phenobarbital and primidone in saliva, plasma and CSF. Epilepsia 16: 735 (1975).

    PubMed  CAS  Article  Google Scholar 

  • Serrano, E.E. and Wilder, B.J.: Intramuscular administration of diphenylhydantoin. Histologic follow-up. Archives of Neurology (Chicago) 31: 276–278 (1974).

    CAS  Article  Google Scholar 

  • Sherwin, A.L.; Eisen, A.A. and Sokolowski, C.D.: Anticonvulsant drugs in human epileptogenic brain. Archives of Neurology (Chicago) 29: 73–77 (1973).

    CAS  Article  Google Scholar 

  • Sherwin, A.L.; Harvey, C.D.; Leppik, I.E. and Gonda, A.: Correlation between red cell and free plasma phenytoin levels in renal disease. Neurology (Minneapolis) 26: 874–878 (1976).

    CAS  Article  Google Scholar 

  • Sherwin, A.L.; Loynd, J.S., Bock, G.W. and Sokolowski, C.D.: Effects of age, sex, obesity and pregnancy on plasma diphenylhydantoin levels. Epilepsia 15: 507–521 (1974).

    CAS  Google Scholar 

  • Shoeman, D.W. and Azarnoff, D.L.: The alteration of plasma proteins in uraemia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology 7: 169–177 (1972).

    PubMed  CAS  Article  Google Scholar 

  • Sjoholm, I.; Kober, A.; Odar-Cederlof, I. and Borga, O.: Protein binding of drugs in uremia and normal serum: the role of endogenous binding inhibitors. Biochemical Pharmacology 25: 1205–1213 (1976).

    PubMed  CAS  Article  Google Scholar 

  • Smith, T.C. and Kinkel, A.: Absorption and metabolism of Phenytoin from tablets and capsules. Clinical Pharmacology and Therapeutics 20: 738–742 (1976).

    PubMed  CAS  Google Scholar 

  • Stewart, M.J.; Ballinger, B.R.; Devlin, E.; Miller, A. and Ramsay, A.C.: Bioavailability of Phenytoin — a comparison of two preparations. European Journal of Clinical Pharmacology 9: 209–212 (1975).

    PubMed  CAS  Article  Google Scholar 

  • Strandjord, R.E. and Johannessen, S.I.: One daily dose of diphenylhydantoin for patients with epilepsy. Epilepsia 15: 317–327 (1974).

    PubMed  CAS  Article  Google Scholar 

  • Svensmark, O. and Buchthal, F.: Diphenylhydantoin and phenobarbital. Serum levels in children. American Journal of Diseases of Children 108: 82–87 (1964).

    CAS  Google Scholar 

  • Tammisto, P.; Kauko, K. and Viukari, M.: Bioavailability of Phenytoin. Lancet 1: 254–255 (1976).

    PubMed  CAS  Article  Google Scholar 

  • Travers, R.; Reynolds, E.H. and Gallagher, B.: Variation in response to anticonvulsants in a group of epileptic patients. Archives of Neurology (Chicago) 27: 29–33 (1972).

    CAS  Article  Google Scholar 

  • Tyrer, J.H.; Eadie, M.J.; Sutherland, J.M. and Hooper, W.D.: Outbreak of anticonvulsant intoxication in an Australian city. British Medical Journal 4: 271–273 (1970).

    PubMed  CAS  Article  Google Scholar 

  • Vajda, F.; Williams, F.M.; Davidson, S.; Falconer, M.A. and Breckenridge, A.: Human brain cerebrospinal fluid and plasma concentrations of diphenylhydantoin and phenobarbital. Clinical Pharmacology and Therapeutics 15: 597–603 (1974).

    PubMed  CAS  Google Scholar 

  • Wallace, S. and Brodie, M.J.: Decreased drug binding in serum from patients with chronic hepatic disease. European Journal of Clinical Pharmacology 9: 429–432 (1976).

    CAS  Article  Google Scholar 

  • Wilder, B.J. and Ramsey, R.E.: Oral and intramuscular Phenytoin. Clinical Pharmacology and Therapeutics 19: 360–364 (1976).

    PubMed  CAS  Google Scholar 

  • Wilder, B.J.; Ramsay, E.: Willmore, L.J.: Feussner, G.F.; Perchalski, R.J. and Shumate, J.B.: Efficacy of intravenous Phenytoin in the treatment of status epilepticus: kinetics of central nervous system penetration. Annals of Neurology 1: 511–519 (1977).

    CAS  Google Scholar 

  • Wilder, B.J.; Serrano, E.E. and Ramsay, E.: Plasma diphenylhydantoin levels after loading and maintenance doses. Clinical Pharmacology and Therapeutics 14: 797–801 (1973).

    PubMed  CAS  Google Scholar 

  • Wilder, B.J.; Serrano, E.E.; Ramsay, E. and Buchanan, R.A.: A method for shifting from oral to intramuscular diphenylhydantoin administration. Clinical Pharmacology and Therapeutics 16: 507–513 (1974).

    PubMed  CAS  Google Scholar 

  • Wilensky, A.J. and Lowden, J.A.: Inadequate serum levels after intramuscular administration of diphenylhydantoin. Neurology (Minneapolis) 23: 318–324 (1973).

    CAS  Article  Google Scholar 

  • Wilson, J.T.; Hojer, B. and Rane, A.: Loading and conventional dose therapy with Phenytoin in children; kinetic profile of parent drug and main metabolite in plasma. Clinical Pharmacology and Therapeutics 20: 48–58 (1976).

    PubMed  CAS  Google Scholar 

  • Yacobi, A.; Lampman, J. and Levy, C.: Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults. Clinical Pharmacology and Therapeutics 21: 283 (1977).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Richens, A. Clinical Pharmacokinetics of Phenytoin. Clin Pharmacokinet 4, 153–169 (1979). https://doi.org/10.2165/00003088-197904030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-197904030-00001

Keywords

  • Clinical Pharmacology
  • Clinical Pharmacokinetic
  • Plasma Protein Binding
  • Rane
  • Epileptic Patient